Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "tyrosine"

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia...

Journal of Clinical Oncology, 1 hour ago
CRIPTO1 role in TKI resistance elucidated News-Medical.Net, 5 days ago

35 images for tyrosine

Sexual Development, 1 week ago
Scientific Computing, 3 weeks ago
SPi World News, 1 month ago
AllAboutFeed.net, 1 month ago
MyScience, 1 month ago
Asian Scientist, 1 month ago
Drug Discovery and Development, 1 month ago
International Journal of Laboratory Hematology, 2 months ago
Chemotherapy Advisor, 2 months ago
Huffington Post UK, 2 months ago

Axl receptor tyrosine kinase expression in breast cancer

Abstract Aims Triple-negative breast cancer comprises a clinically aggressive group of invasive carcinomas. We examined a published gene expression screen of a panel of breast cancer cell lines to identify a ...
 Journal of Clinical Pathology1 week ago CASI receives CFDA approval to conduct Phase II breast cancer trail  Individual.com4 days ago CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For..  ADVFN India1 week ago CASI Pharmaceuticals Receives Approval From To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China  BioSpace1 week ago
[x]  

Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)

KX2-391 is a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. KX2-391 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis via the ...
 Wall Street Select4 days ago Kinex announces allowance of IND application for KX2-391 ointment by USFDA  Pharmaceutical Business Review4 days ago Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis  News-Medical.Net4 days ago
[x]  

Site-Selective Solid-Phase Synthesis of a CCR5 Sulfopeptide Library To Interrogate HIV Binding and Entry

Tyrosine (Tyr) sulfation is a common post-translational modification that is implicated in a variety of important biological processes, including the fusion and entry of human immunodeficiency virus type-1 (HIV-1). A number of sulfated Tyr (sTyr) ...
 ACS Chemical Biology4 days ago

Yes Tyrosine Kinase Inhibitors -Pipeline Insights, 2014

Naperville, IL -- (SBWIRE) -- 07/23/2014 -- Reportstack, provider of premium market research reports announces the addition of market report to its offering DelveInsights,Yes Tyrosine Kinase Inhibitors-Pipeline Insights, 2014, report provides ...
 Town Hall5 days ago Wee1 Tyrosine Kinase Inhibitors -Pipeline Insights, 2014  Wall Street Business Network5 days ago B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014  MarketResearch.com1 week ago Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2014  MarketResearch.com6 days ago
[x]  

Synthesis of Adhesive Peptides Similar to Those Found in Blue Mussel (Mytilus edulis) Using Papain and Tyrosinase

The blue mussel (Mytilus edulis) foot protein 5 (Mefp-5) is an adhesive protein that is mainly composed of glycine, l-lysine, and 3,4-dihydroxy-l-phenylalanine (DOPA). Thousands of adhesive pads have been analyzed in previous studies, whereby it has ...
 Biomacromolecules5 days ago

Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo

Platelet-derived growth factor receptor β (PDGFRβ) is a transmembrane tyrosine kinase receptor involved, for example, in angiogenesis. Overexpression and excessive signaling of PDGFRβ has been observed in multiple malignant tumors and fibrotic ...
 Molecular Pharmaceutics5 days ago

Ignyta launches clinical trials for metastatic cancer drug

US oncology biotech firm Ignyta Inc (NASDAQ:RXDX) said Monday it had begun a Phase I/II study of its oral tyrosine kinase inhibitor, RXDX-101, for the treatment of adults with locally advanced or metastatic cancer confirmed to be positive for ...
 MedCity News1 week ago Targeted therapy for renal cell carcinoma: The next lap - Abstract  UroToday6 days ago Ignyta Announces Initiation of STARTRK-1 Global Phase I/II Clinical Trial of RXDX-101  EON: Enhanced Online News1 week ago Ignyta Inc announces initiation of STARTRK-1 global phase I/II clinical trial of RXDX-101  Reuters UK1 week ago
[x]  

A phase I study of cabozantinib (XL184) in patients with renal cell cancer - Abstract

BACKGROUND: Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC). Renal Cancer ...
 UroToday1 week ago

Ratiometric fluorescent chemosensor based on Tyrosine derivatives for monitoring mercury ions in aqueous solutions

We welcome your comments for improvement of this site and our services. Comments Email ID Security Details ...
 RSC1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less